Premium
The platelet and plasma pools of plasminogen activator inhibitor (PAI‐1) vary independently in disease
Author(s) -
Simpson A. John,
Booth Nuala A.,
Moore Norma R.,
Bennett Bruce
Publication year - 1990
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1990.tb07796.x
Subject(s) - platelet , medicine , plasminogen activator inhibitor 1 , plasminogen activator , endocrinology , diabetes mellitus , thrombosis , cirrhosis , myocardial infarction , gastroenterology
S ummary . The relative importance and behaviour of plasma and platelet plasminogen activator inhibitor (PAI‐1) in disease has not hitherto been examined. In this study the concentration of PAI‐1 in the plasma and platelets of patients with a variety of disorders was examined using a specific ELISA and a functional assay. Mean plasma PAI‐1 was elevated in groups of patients with diabetes mellitus, hypertension, alcoholic cirrhosis, angina and myocardial infarction. Plasma PAI‐1 was raised in the post‐operative phase and the PAI‐1 released after surgery was not derived from platelets. In all groups PAI‐1 in the platelet pool reflected the platelet count, except in type II diabetes mellitus and chronic renal failure, where a reduced quantity of PAI‐1 antigen per platelet was found. In severe chronic renal failure, abnormal platelets and diminished platelet PAI‐1 may contribute to the haemorrhagic tendency sometimes seen in this disorder. Plasma PAI‐1 represents a larger proportion of total circulating PAI‐1 in disease than it does in healthy individuals; PAI‐1 per platelet is abnormal only in a minority of disorders. Plasma and platelet pools of PAI‐1 vary independently in disease and both merit consideration in evaluating the importance, if any, of PAI‐1 in thrombosis or haemorrhage.